Retatrutide + Semaglutide
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Feb 21, 2024 → Jan 1, 2027
NCT ID
NCT06260722About Retatrutide + Semaglutide
Retatrutide + Semaglutide is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is active. This product is registered under clinical trial identifier NCT06260722. Target conditions include Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06260722 | Phase 3 | Active |
Competing Products
20 competing products in Diabetes Mellitus, Type 2